Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Better treatments buoy multiple-myeloma patients, bound by research cuts and racial disparities

2.

Novel Mimetic Bispecific Antibody Superior to Standard Care in Hemophilia A

3.

Advanced Solid Tumors May Benefit from Investigative Immunotherapy Combo.

4.

New opportunities for screening and treatment have been created by the identification of the genetic drivers of esophageal cancer.

5.

For treatment, the majority of cancer patients choose complementary therapies.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot